Surging ahead in the RSV race, Pfizer buys out a PhII player in $525M M&A pact - Endpoints News

Right on the heels of back-to-back breakthrough therapy designations for its lead RSV vaccine, Pfizer is wagering up to $525 million on a biotech buyout that injects new RSV assets into its pipeline. Pfizer is snapping up ReViral after inspecting mid-stage da…

A bruising bear market has left the biotech sector bereft of IPOs in recent months, but in a small sign of market activity, two companies filed to go public over the last two days. On Wednesday, Hil… [+470 chars]

full article...